GlassScriptPhysician profile
Ashley Mowl
NPI 1467477265
$50,888.27
in general payments reported to CMS, 2019-2025
18 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,442 · 2020: $549 · 2021: $3,305 · 2022: $9,103 · 2023: $12K · 2024: $7,505 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Travel and Lodging: $13K · Food and Beverage: $3,286 · Gift: $1.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,670.00 |
| Travel and Lodging | $12,531.38 |
| Food and Beverage | $3,286.02 |
| Gift | $1.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $46,139.55 | 2019-2025 | |
| Coopervision INC. | $1,623.68 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens |
| Bausch & Lomb Americas INC. | $552.01 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $545.75 | 2019-2022 | |
| Biotissue Holdings INC. | $423.30 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $300.23 | 2019-2023 | |
| Abbvie INC. | $246.59 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $204.64 | 2020-2024 | Acuvue |
| Sun Pharmaceutical Industries INC. | $197.84 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $180.87 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $134.99 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $98.85 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $83.01 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $56.36 | 2021 | |
| Alcon Vision LLC | $36.95 | 2021-2025 | Tryptyr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $23.41 | 2019 | |
| Oyster Point Pharma, INC. | $20.84 | 2025 | Tyrvaya, Ryzumvi |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mowl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.